SCHEMBL467203

SCHEMBL467203

CC1(C)C2CC[C@@]1(CS(=O)(=O)Cl)C(=O)C2

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.68
ALDH1A1 P00352 2/20 0.63
F2 P00734 2/20 0.62
PRSS1 P07477 2/20 0.62
PRSS2 P07478 2/20 0.62
PRSS3 P35030 2/20 0.62
MEN1 O00255 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
CYP1A2 P05177 1/20 0.58
CYP2C19 P33261 1/20 0.58
KDM4E B2RXH2 1/20 0.55
CA1 P00915 5/20 0.53
CA2 P00918 5/20 0.53
CA5A P35218 5/20 0.53
CA5B Q9Y2D0 5/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
GAA P10253 1/20 0.52
PKM P14618 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735400 1.00 KMT2A (0.68) KMT2AALDH1A1F2PRSS1PRSS2
SCHEMBL31689627 1.00 KMT2A (0.68) KMT2AALDH1A1F2PRSS1PRSS2
SCHEMBL3782036 1.00 KMT2A (0.68) KMT2AALDH1A1F2PRSS1PRSS2
SCHEMBL20729441 1.00 KMT2A (0.68) KMT2AALDH1A1F2PRSS1PRSS2
SCHEMBL1500774 1.00 KMT2A (0.68) KMT2AALDH1A1F2PRSS1PRSS2
SCHEMBL12706679 1.00 KMT2A (0.68) KMT2AALDH1A1F2PRSS1PRSS2
SCHEMBL23124424 1.00 KMT2A (0.68) KMT2AALDH1A1F2PRSS1PRSS2
SCHEMBL10000728 0.85 KMT2A (0.70) KMT2AALDH1A1F2PRSS1PRSS2
SCHEMBL5960692 0.85 KMT2A (0.70) KMT2AALDH1A1F2PRSS1PRSS2
SCHEMBL1362019 0.85 KMT2A (0.70) KMT2AALDH1A1F2PRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112029041-B Preparation method and application of porous silicon-based microspheres loaded with poly (propargyl) helical polymer 哈尔滨工程大学 2021-05-18 CN claimed
CN-112029041-A Preparation method and application of porous silicon-based microspheres loaded with poly (propargyl) helical polymer 哈尔滨工程大学 2020-12-04 CN claimed
WO-2025122953-A1 DOSING REGIMENS AND FORMULATIONS OF SUZETRIGINE FOR USE IN THE TREATMENT OF ACUTE AND CHRONIC PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-06-12 WO disclosed
US-20250186419-A1 DOSING REGIMENS FOR TREATING PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-06-12 US disclosed
EP-3917907-B1 MODULATORS OF POTASSIUM ION CHANNELS AND USES THEREOF UNIV DEGLI STUDI DI SALERNO (IT) 2025-05-21 EP disclosed
US-20250115687-A1 PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, AND CATALYST FOR POLYMERIZAING OLEFINS FORMOSA PLASTICS CORP USA (US) 2025-04-10 US disclosed
US-20240253023-A1 PERFLUORINATED AMIDE SALTS AND THEIR USES AS IONIC CONDUCTING MATERIALS MICHOT CHRISTOPHE (FR) 2024-08-01 US disclosed
CN-111225896-B Immunomodulatory compounds 凯莫森特里克斯股份有限公司 2024-03-26 CN disclosed
CN-117164587-A Ester group-containing substituted evodiamine derivative, preparation method and application 南华大学附属第一医院 2023-12-05 CN disclosed
CN-116874532-A High-efficiency preparation method and application of 4-hydrobenzo [1,2] azaphosphine-3-ketone-1-oxide series compound 浙大城市学院 2023-10-13 CN disclosed
US-11708326-B2 Immunomodulator compounds CHEMOCENTRYX, INC. (US) 2023-07-25 US disclosed
WO-1998000395-A1 PHENYLALAMINE DERIVATIVES AS INTEGRIN INHIBITORS MERCK PATENT GMBH (DE) 1998-01-08 WO disclosed
EP-0777660-A1 NOVEL ALKYLAMINO DERIVATIVES AS SIGMA 2 SELECTIVE LIGANDS MITSUBISHI CHEMICAL CORPORATION (JP) 1997-06-11 EP disclosed
EP-0654028-B1 3- AND 5-SUBSTITUTED 1,2,3,4-OXATRIAZOLE-5-IMINE COMPOUNDS, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL PREPARATION CONTAINING SAID COMPOUNDS AND THE USE OF SAID COMPOUNDS FOR THE PREPARATION OF MEDICAMENTS GEA FARMACEUTISK FABRIK AS (DK) 1996-04-17 EP disclosed
WO-1996005185-A1 NOVEL ALKYLAMINO DERIVATIVES AS SIGMA 2 SELECTIVE LIGANDS MITSUBISHI CHEMICAL CORPORATION (JP) 1996-02-22 WO disclosed
US-5424306-A Storage stable SANKYO COMPANY, LIMITED (JP) 1995-06-13 US disclosed
US-5352822-A Insecticides; miticides; nematocides ROUSSEL UCLAF (FR) 1994-10-04 US disclosed
US-5229424-A Insecticides, acaricides THE WELLCOME FOUNDATION LIMITED (GB) 1993-07-20 US disclosed
US-5175159-A Prevention of premature labor MERCK & CO., INC. (US) 1992-12-29 US disclosed
EP-0421802-A2 3-substituted-1,4-benzodiazepines useful as oxytocin antagonists MERCK & CO. INC. (US) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708326-B2 Immunomodulator compounds IL2, FCGRT, IFNG KMT2A 2193/4885ALDH1A1 877/4885F2 677/4885
US-20250186419-A1 DOSING REGIMENS FOR TREATING PAIN OPRL1, OPRK1, TRPV1 KMT2A 3847/4885ALDH1A1 413/4885F2 3346/4885
US-20240253023-A1 PERFLUORINATED AMIDE SALTS AND THEIR USES AS IONIC CONDUCTING MATERIALS AFF4, AFF2, AFF1 KMT2A 1243/4885ALDH1A1 1811/4885F2 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.